On the evening of January 19th that Mingde Biotechnology...(002932) issued an announcement stating that the company plans to acquire Lanyi (Hunan) Medical Devices in the first phase of the acquisition through capital increase and equity acquisition.The company acquired 51% equity in Hunan Lanyi Limited Company (hereinafter referred to as "Hunan Lanyi"). After the initial acquisition, Hunan Lanyi became a controlling subsidiary of the company and was included in the company's consolidated financial statements. Through negotiation among the parties involved, the total transaction price for this capital increase and equity acquisition of 51% equity in Hunan Lanyi was RMB 35.701 million.

Meanwhile, if Hunan Lanyi's relevant operating conditions from 2026 to 2028 meet the relevant preconditions stipulated in the Acquisition Agreement, the Company will further acquire the remaining equity of Hunan Lanyi in accordance with the agreement. After the completion of the aforementioned two-stage acquisition, the Company will hold a total of 100% equity of Hunan Lanyi.

The announcement shows that Hunan Lanyi was established in September 2020, focusing on the research, development, production and service of IVD instruments and reagents, and has been awarded the titles of National High-tech Enterprise and Specialized, Refined and Innovative Enterprise.The "Little Giant" has mastered high-performance liquid chromatography (HPLC) in the detection of glycated hemoglobin. With the AH-600 series glycated hemoglobin analysis system as its core, related detection products have become core products for domestic substitution and chronic disease management due to their advantages of accuracy, efficiency, authoritative certification, and controllable cost.

Mindray Bio -Medical Electronics stated that Hunan Lanyi is currently experiencing losses due to significant upfront investment in product development and substantial temporary and strategic market investments during the market expansion phase. With the inclusion of glycated hemoglobin in the national free health check-up program for individuals aged 65 and above, procurement demand from primary healthcare institutions is expected to increase. Coupled with continued growth in overseas business, the glycated hemoglobin business is projected to become the core growth engine for the target company, supporting its future performance improvement.

https://finance.eastmoney.com/a/202601193623465579.html